TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorShenzhen TargetRx Co., Ltd.
About this trial
A Phase III study evaluating the safety and efficacy of TGRX-678 in CML-CP patients resistant from or intolerant to at least 3 TKIs
Eligibility criteria
Qualifiers
Willing to consent and to follow study procedures
18 years of age or above at time of screening; both sexes eligible
Diagnosed with CML-CP and was intolerant to or failed from at least 3 TKI treatments
ECOG score >= 2
Disqualifiers
Reception of TKI treatment or other anti-tumor treatments prior to first dose
History or presence of extramedullary leukemia
History of progression to CML-AP or BP
Presence or having uncontrolled condition for cardiovascular diseases
Trial design
Treatments tested in this trial
- TGRX-678
- TKI
Treatment groups
180 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov